Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20887133 | 0.76 | CES1 (0.41) | ALDH1A1MAPTL3MBTL1NSD2EGFR | |
| SCHEMBL7582626 | 0.75 | PARP1 (0.63) | — | |
| SCHEMBL19586356 | 0.74 | ALDH1A1 (0.42) | ALDH1A1GAAKDM4EHPGDKMT2A | |
| SCHEMBL4819056 | 0.74 | KEAP1 (0.54) | ALDH1A1GAAKDM4EHPGDTYMS | |
| SCHEMBL29495011 | 0.74 | PARP1 (0.56) | ALDH1A1GAAKDM4EHPGDTYMS | |
| SCHEMBL163780 | 0.74 | PARP1 (0.56) | ALDH1A1GAAKDM4EHPGDTYMS | |
| SCHEMBL14596266 | 0.73 | LMNA (0.45) | ALDH1A1MAPTL3MBTL1NSD2EGFR | |
| SCHEMBL6837520 | 0.73 | MAPT (0.44) | ALDH1A1MAPTL3MBTL1NSD2EGFR | |
| SCHEMBL30524295 | 0.72 | GFER (0.50) | ALDH1A1MAPTL3MBTL1NSD2EGFR | |
| SCHEMBL5541367 | 0.71 | ALDH1A1 (0.41) | ALDH1A1MAPTGAAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006020070-A2 | INDANYLAMINO URACILS AND THEIR USE AS ANTIOXIDANTS AND NEUROPROTECTANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | ALDH1A1 3901/4885MAPT 2427/4885L3MBTL1 3013/4885 |
| US-20070021450-A1 | Indanylamino uracils and their use as antioxidants and neuroprotectants | OGG1, CBR3, C1R | ALDH1A1 1798/4885MAPT 2087/4885L3MBTL1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.